Clinical Trials Logo

Seizures clinical trials

View clinical trials related to Seizures.

Filter by:

NCT ID: NCT02746965 Terminated - Schizophrenia Clinical Trials

Magnetic Seizure Therapy for Schizophrenia

Start date: March 1, 2017
Phase: N/A
Study type: Interventional

This trial attempts to evaluate the treatment efficacy of magnetic seizure therapy (MST) and its safety among schizophrenia patients. Half of the participants will be randomized to MST group, while the other half will be randomized to receive electroconvulsive therapy (ECT).

NCT ID: NCT02736162 Completed - Epilepsy Clinical Trials

Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy

Start date: April 2016
Phase: N/A
Study type: Observational

The primary objective of this study is to assess the retention rate of perampanel when given as secondary monotherapy in routine clinical care.

NCT ID: NCT02726074 Completed - Epilepsy Clinical Trials

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Start date: May 3, 2016
Phase: Phase 4
Study type: Interventional

This is a multi-center, open-label, single-arm, phase 4 study to evaluate the efficacy of perampanel added to monotherapy for partial onset seizures with or without secondarily generalized seizures (total seizures).

NCT ID: NCT02724423 Completed - Clinical trials for Acute Repetitive Seizures

Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects

Start date: June 30, 2016
Phase: Phase 1
Study type: Interventional

This study evaluates the pharmacokinetic and safety of NRL-1 in epilepsy subjects. Subjects will receive a single intranasal dose of NRL-1 of either 5 mg, 10 mg, 15 mg or 20 mg and will be based on the subject's body weight.

NCT ID: NCT02721069 Completed - Clinical trials for Acute Repetitive Seizures

Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects

Start date: April 11, 2016
Phase: Phase 3
Study type: Interventional

This is a 12 month safety study to evaluate the safety of repeated doses of NRL-1

NCT ID: NCT02705768 Completed - Seizures, Focal Clinical Trials

Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures

Start date: April 2016
Phase: Phase 4
Study type: Interventional

The present study has been planned to assess the level of serum neuron-specific enolase (NSE) in focal seizures and its changes after antiepileptic therapy.

NCT ID: NCT02700412 Completed - Epilepsy Clinical Trials

University of Alabama at Birmingham (UAB) Adult CBD Program

Start date: April 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.

NCT ID: NCT02695537 Completed - Epilepsy Clinical Trials

University of Alabama at Birmingham (UAB) Pediatric CBD Program

Start date: April 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability of Epidiolex at various doses between 5 mg/kg/day and 50 mg/kg/day as an additional (add-on) drug for treating debilitating, drug-resistant epilepsy.

NCT ID: NCT02694094 Enrolling by invitation - Epilepsy Clinical Trials

Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy

Start date: March 2016
Phase:
Study type: Observational

This research is being done to evaluate the short term and long term effects of ketogenic diets on measures of cardiovascular health. Such measures include cholesterol levels, blood pressure, weight, and thickening of the blood vessel wall over time. Adults aged 18 or older who are already on a ketogenic diet for at least 12 months or who are interested in beginning on the modified Atkins diet may join.

NCT ID: NCT02687711 Completed - Clinical trials for Epilepsy With POS With or Without Secondary Generalization

Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures

BASE
Start date: February 1, 2016
Phase:
Study type: Observational

Study is the first study after commercialization of brivaracetam. It is designed to collect real world information on the effectiveness of brivaracetam in patients with Partial Onset Seizure epislepsy who are treated in standard clinical practice.